Literature DB >> 9458980

In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.

D G Schick1, H N Canawati, J Z Montgomerie.   

Abstract

The activities of trovafloxacin and ciprofloxacin against 38 strains of non-beta-lactamase-producing enterococci, resistant to ampicillin, 34 strains susceptible to ampicillin, and 3 vancomycin-resistant enterococci were studied. Trovafloxacin was more active than ciprofloxacin against all the enterococci studied. The ampicillin-resistant strains were more susceptible than the ampicillin-susceptible strains to both agents. The effect of combining trovafloxacin with gentamicin, ampicillin-sulbactam, novobiocin, rifampin, teicoplanin, and vancomycin was determined for 17 strains by the checkerboard method. An additive effect by inhibition was seen with all antibiotics studied. The results by killing varied with the different agents studied. Gentamicin, ampicillin-sulbactam, and novobiocin produced an additive killing effect with trovafloxacin. Reduced killing was seen when rifampin, vancomycin, or teicoplanin were added to trovafloxacin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9458980     DOI: 10.1016/s0732-8893(97)00161-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Comparative killing rates of fluoroquinolones and cell wall-active agents.

Authors:  J C Fung-Tomc; E Gradelski; L Valera; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Treatment of enterococcal pyelonephritis with trovafloxacin and rifampin: in vitro-in vivo contrast.

Authors:  J Z Montgomerie; D G Schick
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

3.  Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.

Authors:  Neil R Stokes; Helena B Thomaides-Brears; Stephanie Barker; James M Bennett; Joanne Berry; Ian Collins; Lloyd G Czaplewski; Vicki Gamble; Paul Lancett; Alastair Logan; Christopher J Lunniss; Hilary Peasley; Stéphanie Pommier; Daniel Price; Carol Smee; David J Haydon
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.